The success of GLP-1s like Ozempic, which address weight loss, addiction, and metabolic fitness, has made the public more receptive to longevity drugs. People now better understand how a single drug targeting a core mechanism (like metabolic health) can have widespread, seemingly magical downstream benefits.

Originally for diabetes, GLP-1s' broad positive effects on inflammation, heart, and brain function position them as the first mainstream drugs for human enhancement and longevity, moving beyond simple disease management.

Weight-loss drugs like Ozempic have moved from a niche medical treatment to a mainstream phenomenon, with new data showing 15.2% of all American women are now taking them. This rapid, large-scale adoption signifies a major public health shift that will have downstream effects on the food, fitness, and healthcare industries.

The widespread adoption of GLP-1 drugs for obesity, projected to reach 25 million U.S. users, will significantly reduce food, soda, and alcohol consumption. This presents a material, long-term revenue threat to consumer-facing industries like fast food, snack companies, and even casinos, forcing investors in those sectors to adjust their models.

Beyond tackling fatal diseases to increase lifespan, a new wave of biotech innovation focuses on "health span"—the period of life lived in high quality. This includes developing treatments for conditions often dismissed as aging, such as frailty, vision loss, and hearing decline, aiming to improve wellbeing in later decades.

Scott Galloway argues GLP-1 drugs (like Ozempic) will have a greater societal impact than AI. By tackling obesity, they could halve U.S. healthcare costs, help solve the deficit, and even curb addictions, making them a profoundly transformative technology.

The long-held belief that solving obesity would create immense wealth is now validated by Eli Lilly's $1T market cap, driven by its GLP-1 weight-loss drugs. This marks a significant shift, as the trillion-dollar club was previously dominated by tech and oil companies.

The growing use of various peptides within the biohacking community acts as an early indicator for broader societal adoption. Much like creatine moved from bodybuilding circles to the mainstream, these 'fringe' health practices are a leading signal for future large-scale consumer health markets.

Current healthcare spending, or "Aging 1.0," focuses on managing age-related decline via retirement homes and late-stage care. The new paradigm, "Aging 2.0," uses biotechnology to prevent the need for this maintenance in the first place, representing a fundamental strategic shift.